KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC – Targeted Oncology

0
95
Advertisment



KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC  Targeted Oncology



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here